FDA Approves New Indication for Avapritinib

Avapritinib (AYVAKIT) is now approved to treat adults with indolent systemic mastocytosis.

Related Keywords

Judith Kain Emmel ,Blueprint Medicines Corp ,Drug Administration ,Mast Cell Disease Society ,Kain Emmel ,Lysosomal Storage Disease ,Systemic Mastocytosis ,Mastocytosis ,Peripheral Edema ,Bedema ,Bone Marrow ,Platelet Growth Factor ,Platelet Derived Growth Factor ,Tyrosine Kinase Inhibitor ,Rlotinib ,Efitinib ,Matinib ,U11248 ,Unitinib ,Biologic Therapy ,Gist ,Gastrointestinal Stromal Tumor ,Umor Gastrointestinal Stromal ,Boards ,Smle ,Bones ,Dizziness ,Hematologic Disorders ,I Cell Disease ,Ucolipidosis T ,